NasdaqGS - Nasdaq Real Time Price USD

Atea Pharmaceuticals, Inc. (AVIR)

3.6900 -0.0100 (-0.27%)
At close: April 25 at 4:00 PM EDT
3.7200 +0.03 (+0.81%)
After hours: April 25 at 5:17 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, CEO & President 1.1M -- 1956
Ms. Andrea J. Corcoran J.D. CFO, Executive VP of Legal & Secretary 732.45k -- 1962
Mr. John F. Vavricka Chief Commercial Officer 581.11k -- 1964
Dr. Janet M. J. Hammond M.D., Ph.D. Chief Development Officer 817.16k -- 1961
Dr. Maria Arantxa Horga M.D. Chief Medical Officer 695.85k -- 1969
Mr. Wayne Foster CPA Executive VP of Finance & Chief Accounting Officer -- -- 1969
Ms. Jonae R. Barnes Senior Vice President of Investor Relations & Corporate Communications -- -- --
Mr. Ariyapadi N. Krishnaraj Vice President of Marketing -- -- --
Mr. Adel Moussa Ph.D. Executive Vice President of Chemistry -- -- --
Mr. Xiao-Jian Zhou Ph.D. Executive Vice President of Early Stage Development -- -- --

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891 https://ateapharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
75

Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate Governance

Atea Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Atea Pharmaceuticals, Inc. Earnings Call

Related Tickers

RPHM Reneo Pharmaceuticals, Inc.
1.6500
-1.79%
 
CTMX CytomX Therapeutics, Inc.
1.6000
-1.84%
 
NXTC NextCure, Inc.
1.2900
-10.42%
 
ACHL Achilles Therapeutics plc
0.7744
-1.91%
 
ALVR AlloVir, Inc.
0.8000
+2.56%
 
ASMB Assembly Biosciences, Inc.
13.36
-0.67%
 
TIL Instil Bio, Inc.
10.40
-1.89%
 
EIGRQ Eiger BioPharmaceuticals, Inc.
3.0400
-19.95%
 
PRTC.L PureTech Health plc
212.50
0.00%
 
ALGS Aligos Therapeutics, Inc.
0.8180
-1.33%